Maria Alice Willrich’s Post

Thyroid eye disease (TED) is an autoimmune condition with only one FDA approved treatment currently available. Longitude portfolio company Viridian Therapeutics, Inc. aims to bring new treatment options to people affected by TED through the development of potential best-in-class monoclonal antibody therapies. IGF-1R, a transmembrane receptor that plays a role in development, metabolism, and immune regulation, is a clinically and commercially validated target for the treatment of #TED. Based on work in the field, IGF-1R and the co-located thyroid stimulating hormone receptor (TSHR) have been found to play a key role in the pathogenesis of TED. Read more about the company's TED clinical development program: https://lnkd.in/efYxbSBp #autoimmunediseases

Viridian Therapeutics announced positive topline data from its phase 3 THRIVE clinical trial (NCT05176639) of veligrotug, previously known as VRDN-001, in patients with active thyroid eye disease (TED). Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.” Furthermore, THRIVE met both the primary and all secondary endpoints at 15 weeks after 5 infusions of veligrotug. Additionally, veligrotug showed a rapid onset of action, with the majority (53%) of veligrotug-treated patients achieving a proptosis response after just 1 infusion, or 3 weeks after the start of therapy. Read more: https://lnkd.in/e6j5AZih

Kidney Awareness Month during March is a particularly meaningful time for us here at Memo Therapeutics, given the many challenges facing Chronic Kidney Disease (#CKD) patients, especially those needing kidney transplantation. With approximately 500,000 people requiring end stage renal disease dialysis support and 100,000 people waiting for kidney transplants in the US alone, early diagnosis and pre-emptive treatment could save thousands of patients’ lives and preserve the quality of life for many others. At Memo Therapeutics, we have used our innovative antibody discovery platform to develop a monoclonal antibody, now in Phase II clinical development, to target BK virus: a major contributor to post-transplantation complications and ultimately graft loss. Read more about our program here:  https://lnkd.in/en6ZhHbV #KidneyAwarenessMonth #KidneyHealth #TransplantsforAll #MemoTherapeutics #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #DrugDiscovery  

Therapeutic monoclonal antibodies #mAbs and antibody-drug-conjugates #ADCs by Top-Down and Middle-Down MS. Join us April 25 for Benqian Wei's seminar on internal fragments, mAbs and ADCs. #proteomics #TeamMassSpec https://lnkd.in/epcuuWaq Neil Kelleher Ying Ge Joseph Loo Julia Chamot-Rooke Benqian Wei Mowei Zhou

Johnson & Johnson entered into an #agreement with Numab Therapeutics AG to acquire the global rights for Phase 2-ready bispecific antibody NM26. The experimental #eczema treatment is a new type of drug that targets two proteins that cause the itchiness and inflammation of #atopicdermatitis. This is the second bispecific antibody deal J&J has signed, after the May 16 deal to acquire Proteologix for $850 million. #immunology 

Don't miss the #VT1021 update from Vigeo Therapeutics COO Dr. Jing Watnick at the Fifth Annual Glioblastoma Drug Development Summit in Boston MA this week. Dr. Watnick will be speaking during the afternoon session on 28 March on The #VT1021 Ph1/2 clinical program in #glioblastoma as well the potential future use of #VT1021 in Neuro-inflammatory diseases #GBM #Glioblastoma #NeuroinflammatoryDiseases #VT1021

[Clinical Trials] NeuroSense Therapeutics reports phase 2b trial results of PrimeC in ALS indicating reduced risk of disease complications and slower progression https://lnkd.in/gntGVcH8 CymaBay Therapeutics' phase 3 trial of seladelpar yields significant efficacy in primary biliary cholangitis endpoints https://lnkd.in/gu_sAxbc SynAct Pharma reports phase 2b trial of AP1189 reveals efficacy endpoints met in Rheumatoid Arthritis patients with elevated baseline CRP https://lnkd.in/g4KMythz [Deals] Immunocore Holdings and 브리스톨마이어스스큅 Collaborate on phase 3 Clinical Trial for IMC-F106C in Cutaneous Melanoma Treatment https://lnkd.in/gUchXuzB

𝐆𝐥𝐞𝐧𝐦𝐚𝐫𝐤 𝐆𝐞𝐭𝐬 𝐂𝐃𝐒𝐂𝐎 𝐏𝐚𝐧𝐞𝐥 𝐍𝐨𝐝 𝐭𝐨 𝐒𝐭𝐮𝐝𝐲 𝐈𝐒𝐁 𝟐𝟎𝟎𝟏 𝐢𝐧 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐌𝐲𝐞𝐥𝐨𝐦𝐚 📌Glenmark has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical study of the anticancer drug ISB 2001 in relapsed/refractory multiple myeloma. 📌Glenmark presented Phase 1 clinical study protocol No. ISB 2001-101 version 2.0 amendment 01 dated 07/April/2023. This study is a first-in-human, Phase 1, open-label study that will evaluate the safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma. 📌Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help fight infections by making proteins called antibodies. Antibodies find and attack germs. In multiple myeloma, cancerous plasma cells build up in the bone marrow. 📌ISB 2001 is a triple-target antibody, meaning the therapy has three arms — each one reaching out and interacting with a different target. Those targets are CD38, BCMA, and CD3. 📌At the recent SEC meeting for oncology held on the 7th and 8th of February 2023, the expert panel reviewed the Phase I clinical study protocol No. ISB 2001-101 version 2.0 amendment 01 dated 07/April/2023. #cdsco #glenmark #anticancer #myeloma #clinicaltrial

Our Senior Director, Protein Engineering Gregory Moore gave a presentation entitled "Modulating the immune system with CD28 costimulatory bispecific antibodies” at the Festival of Biologics in San Diego and discussed this novel approach to utilize bispecific T cell engagers for the potential treatment of patients with multiple solid tumor types. Click the link for more information on our clinical pipeline, including our leading tumor-selective costimulating bispecific antibody, XmAb808. #festivalofbiologics #proteinengineering #bispecificantibodies

What I Read Today... - "Regeneron & Sanofi: Dupixent Approved in USA & China as the First-ever Biologic Medicine for Patients with COPD (Chronic Obstructive Pulmonary Disease)... COPD is a respiratory disease that damages the lungs and causes progressive lung function decline and is the fourth leading cause of death worldwide. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant... - "Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients... Multiple myeloma is a cancer that affects the bone marrow and causes abnormal plasma cells to build up and form tumors in the bones P-BCMA-ALLO1 is an allogeneic CAR-T product candidate licensed to Roche targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma..."